Target Age-Related Diseases
The Challenge
Age-related diseases such as neurodegeneration, obesity, and metabolic disorders are among the greatest global health burdens.
Researchers and innovators face the daunting task of translating discoveries into therapies that can slow, prevent, or reverse these conditions.
Yet current in vivo preclinical models are often time-consuming and too costly, leading to high attrition rates in later-stage trials.
Key trends
By 2050, over 1.5 billion people will be aged 65 or older, making age-related diseases a defining medical challenge of our century.
The neurodegeneration therapeutics market is expanding rapidly, driven by the rising prevalence of Alzheimer’s, Parkinson’s, and related disorders, underscoring the urgency for better discovery and validation tools.
There is a clear opening for innovative solutions that enable faster, more predictive, and ethically responsible research into age-related diseases.
With such tools, researchers can accelerate the discovery of interventions that truly improve patient lives.
Automated in vivo results at the in vitro scale:
fast, ethical, and translational solutions
Disease-Relevant in vivo Model
Access a proven in vivo model that speaks the same biological language as human aging. Using C. elegans, we help you rapidly identify compounds that impact healthspan and longevity — ethically, reproducibly, and with direct translational relevance.
Automated, High-Throughput Screening
From experiment design to data analysis, we deliver actionable insights so you can move faster and with confidence.
Are you interested in our flagship solution at your site? Our SydLab™ One platform enables large-scale in vivo testing with reproducible, automated results — saving time and resources while revealing your most promising candidates.
Mechanistic and Biomarker Insights
We combine multi-phenotypic analysis with advanced biological metrics, such as biological age prediction and pathway-specific readouts using fluorescent markers and omic approaches. This equips you with mechanistic understanding, not just outcome data, to be able to de-risk your preclinical programs.
The Swiss Knife Solution for Healthy Aging Discoveries
Nagi™ C-Age
High-throughput in vivo measurement of lifespan and motility.
Multidimensional insights in a single assay.
Nagi™ B-Age
AI-powered in vivo biological age and healthspan measurement to fast-track your innovation in just 10 days.
Dissect the mechanism of action among 5 vital traits.
Recent Projects
With Nagi Bioscience, you gain:
Accelerated discovery timelines
Biological Age insights in as little as 10 days; lifespan and disease-relevant outcomes within weeks.
Reduced translational risk
Screen and validate in vivo compounds earlier, before investing heavily in vertebrate studies.
Scalable innovation capacity
Enable rapid lead prioritization.
Mechanistic depth
Access robust biomarker and pathway data to strengthen your therapeutic hypotheses.
Ethical and cost-efficient research
Reduce costs and your ethical hurdles when applying for vertebrate studies using data rich analysis that justify downstream experiments.
From early-stage discovery to preclinical validation, Nagi Bioscience empowers researchers to fight age-related diseases with confidence, speed, and scientific rigor.
“We are very pleased with Nagi Bioscience. Their innovative technology has been instrumental in allowing us to gather critical scientific data quickly, providing invaluable insights that significantly advance our research in longevity.“
“We had a highly positive experience with Nagi’s services. Their innovative assays provided a reliable alternative to mouse studies by leveraging the short lifespan of C. elegans and the high conservation of our target from worms to human.“
“Their high-throughput approach provided clear, quantifiable insights into the lifespan and functional effects of our lead combinations— critical data that helped de-risk and prioritize our therapeutic strategy.“